[go: up one dir, main page]

PL1663287T3 - Zastosowanie zmodyfikowanych cyklosporyn do leczenia schorzeń wywołanych przez HCV - Google Patents

Zastosowanie zmodyfikowanych cyklosporyn do leczenia schorzeń wywołanych przez HCV

Info

Publication number
PL1663287T3
PL1663287T3 PL04764762T PL04764762T PL1663287T3 PL 1663287 T3 PL1663287 T3 PL 1663287T3 PL 04764762 T PL04764762 T PL 04764762T PL 04764762 T PL04764762 T PL 04764762T PL 1663287 T3 PL1663287 T3 PL 1663287T3
Authority
PL
Poland
Prior art keywords
treatment
hcv
disorders
cyclosporins
modified
Prior art date
Application number
PL04764762T
Other languages
English (en)
Inventor
Makoto Hijikata
Kunitada Shimotohno
Koichi Watashi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1663287T3 publication Critical patent/PL1663287T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL04764762T 2003-09-03 2004-09-02 Zastosowanie zmodyfikowanych cyklosporyn do leczenia schorzeń wywołanych przez HCV PL1663287T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds
PCT/EP2004/009804 WO2005021028A1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders
EP04764762A EP1663287B1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders

Publications (1)

Publication Number Publication Date
PL1663287T3 true PL1663287T3 (pl) 2009-12-31

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04764762T PL1663287T3 (pl) 2003-09-03 2004-09-02 Zastosowanie zmodyfikowanych cyklosporyn do leczenia schorzeń wywołanych przez HCV

Country Status (29)

Country Link
US (1) US7968518B2 (pl)
EP (2) EP1797892B1 (pl)
JP (1) JP4688806B2 (pl)
KR (1) KR101116968B1 (pl)
CN (1) CN1842343A (pl)
AU (2) AU2004268382A1 (pl)
BR (1) BRPI0414062B8 (pl)
CA (1) CA2537137C (pl)
CY (1) CY1110506T1 (pl)
DE (1) DE602004022061D1 (pl)
DK (1) DK1663287T3 (pl)
ES (1) ES2328361T3 (pl)
GB (1) GB0320638D0 (pl)
HR (1) HRP20090535T1 (pl)
IL (1) IL173909A (pl)
IS (1) IS2917B (pl)
MA (1) MA28032A1 (pl)
MX (1) MXPA06002394A (pl)
NO (1) NO20061479L (pl)
NZ (1) NZ545495A (pl)
PL (1) PL1663287T3 (pl)
PT (1) PT1663287E (pl)
RU (1) RU2389501C2 (pl)
SG (1) SG149063A1 (pl)
SI (1) SI1663287T1 (pl)
TN (1) TNSN06071A1 (pl)
TW (1) TWI342782B (pl)
WO (1) WO2005021028A1 (pl)
ZA (1) ZA200601550B (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00013019A (es) 1998-07-01 2003-07-14 Debiopharm Sa Ciclosporina novedosa con perfil de actividad mejorado.
EP1603512A2 (en) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Novel cyclosporins
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
KR20070036175A (ko) * 2004-07-14 2007-04-02 노파르티스 아게 Ｃ형 간염(ｈｃｖ)의 치료를 위한 시클로스포린과ｐｅｇ화된 인터페론의 조합 제제의 용도
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
EA012650B1 (ru) 2004-10-01 2009-12-30 Дебиофарм С.А. ПРИМЕНЕНИЕ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИН
JP5139065B2 (ja) * 2004-10-01 2013-02-06 スシネキス インク Ｃ型肝炎感染の治療及び予防のための３−エーテル及び３−チオエーテル置換シクロスポリン誘導体
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
EP1812037A4 (en) 2004-10-06 2009-11-11 Amr Technology Inc ALKYNES OF CYCLOSPORINE AND THEIR USEFUL AS PHARMACEUTICAL AGENTS
ATE412005T1 (de) 2004-11-22 2008-11-15 Astellas Pharma Inc Zyklosporinanalog
WO2006071619A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
AU2005322241B2 (en) * 2004-12-23 2010-02-18 Novartis Ag Compounds for flaviviridae treatment
CA2611151A1 (en) * 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
ATE498630T1 (de) 2005-09-30 2011-03-15 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
CN105169369B (zh) * 2005-09-30 2019-10-18 中美华世通生物医药科技（武汉）有限公司 治疗和预防丙型肝炎感染的方法和药物组合物
KR101273681B1 (ko) 2005-10-26 2013-06-25 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
JP5377293B2 (ja) 2006-05-19 2013-12-25 スシネキス インク 眼疾患の治療及び予防方法
EP2027761A1 (fr) * 2006-06-02 2009-02-25 Claude Annie Perrichon Gestion des electrons actifs
AU2007306316B2 (en) * 2006-10-12 2011-10-27 Kyushu University Use of modified cyclosporins
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US8450281B2 (en) * 2007-01-04 2013-05-28 Debiopharm S.A. Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
CN101687012A (zh) * 2007-05-02 2010-03-31 安斯泰来制药有限公司 新的环肽化合物
WO2009028418A1 (ja) 2007-08-24 2009-03-05 Sapporo Medical University シクロスポリンａ結合タンパク質
CA2724523A1 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
JP5726733B2 (ja) * 2008-07-30 2015-06-03 シクロフィリン ファーマシューティカルズ コープ． 非免疫抑制性シクロスポリン類似体分子
JP5625910B2 (ja) * 2008-09-24 2014-11-19 アステラス製薬株式会社 ペプチド化合物およびその製造方法
JP5758806B2 (ja) * 2008-11-06 2015-08-05 デビオ ルシェルシュ ファルマスーティク ソシエテ アノニムＤｅｂｉｏ Ｒｅｃｈｅｒｃｈｅ Ｐｈａｒｍａｃｅｕｔｉｑｕｅ Ｓｏｃｉｅｔｅ Ａｎｏｎｙｍｅ シクロウンデカデプシペプチド化合物および医薬としてのその化合物の使用
CN102307892A (zh) * 2008-12-31 2012-01-04 西尼克斯公司 环孢菌素a的衍生物
JP5406943B2 (ja) * 2009-01-30 2014-02-05 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎感染を予防または治療するためのシクロスポリンアナログ
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
JP2013513595A (ja) 2009-12-09 2013-04-22 サイネクシス，インコーポレーテッド 新規環状ペプチド
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
AU2011311706B2 (en) 2010-10-05 2015-11-12 Debiopharm S.A. New treatments of Hepatitis C virus infection
JP6110791B2 (ja) 2010-11-30 2017-04-05 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の新規治療
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
KR20190002731A (ko) 2010-12-15 2019-01-08 콘트라빌 파마슈티컬스, 인코퍼레이티드 아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자
MX2013011256A (es) 2011-03-31 2013-10-17 Novartis Ag Alisporivir para el tratamiento de la infeccion por el virus de hepatitis c.
RU2013148779A (ru) 2011-04-01 2015-05-10 Новартис Аг Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
US20150104415A1 (en) 2011-04-13 2015-04-16 Debiopharm International Sa Treatments of Hepatitis C virus infection
AU2012314517A1 (en) 2011-09-27 2014-04-17 Novartis Ag Alisporivr for treatment of Hepatis C virus infection
CN104284671A (zh) 2012-05-07 2015-01-14 诺华股份有限公司 使用阿拉泊韦的药代动力学调节
EP3263587A1 (en) 2012-06-01 2018-01-03 Allergan, Inc. Cyclosporin a analogs
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
EP3038626A4 (en) 2013-08-26 2017-04-19 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
CA3192515A1 (en) * 2020-08-24 2022-03-03 Nanomerics Limited Viral inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
ES2171191T3 (es) 1994-08-22 2002-09-01 Mitsubishi Pharma Corp Compuesto de benceno y uso medicinal del mismo.
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
SI1002792T1 (en) 1997-04-04 2004-12-31 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
MXPA00013019A (es) 1998-07-01 2003-07-14 Debiopharm Sa Ciclosporina novedosa con perfil de actividad mejorado.
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
US20040033946A1 (en) * 2000-10-19 2004-02-19 Futoshi Shibasaki Cell damage inhibitor
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
PL367348A1 (pl) 2001-03-26 2005-02-21 Novartis Ag Pochodne 2-amino-propanolu
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US20030213603A1 (en) 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
EA012650B1 (ru) 2004-10-01 2009-12-30 Дебиофарм С.А. ПРИМЕНЕНИЕ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИН
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
BRPI0414062A (pt) 2006-10-24
US20070275884A1 (en) 2007-11-29
KR20060132798A (ko) 2006-12-22
CN1842343A (zh) 2006-10-04
EP1797892B1 (en) 2013-10-23
BRPI0414062B1 (pt) 2019-06-25
GB0320638D0 (en) 2003-10-01
EP1797892A1 (en) 2007-06-20
AU2008203031B2 (en) 2011-04-07
EP1663287A1 (en) 2006-06-07
EP1663287B1 (en) 2009-07-15
TWI342782B (en) 2011-06-01
IS2917B (is) 2014-12-15
HRP20090535T1 (hr) 2009-11-30
WO2005021028A1 (en) 2005-03-10
IL173909A0 (en) 2006-07-05
HK1091732A1 (en) 2007-01-26
TW200524626A (en) 2005-08-01
JP4688806B2 (ja) 2011-05-25
ES2328361T3 (es) 2009-11-12
MA28032A1 (fr) 2006-07-03
TNSN06071A1 (en) 2007-10-03
SI1663287T1 (sl) 2009-10-31
MXPA06002394A (es) 2006-06-20
JP2007504260A (ja) 2007-03-01
US7968518B2 (en) 2011-06-28
CA2537137A1 (en) 2005-03-10
IS8371A (is) 2006-03-24
ZA200601550B (en) 2007-05-30
PT1663287E (pt) 2009-09-03
NZ545495A (en) 2010-01-29
AU2008203031A1 (en) 2008-07-31
DK1663287T3 (da) 2009-11-09
RU2389501C2 (ru) 2010-05-20
SG149063A1 (en) 2009-01-29
RU2006110533A (ru) 2007-10-10
BRPI0414062B8 (pt) 2021-05-25
AU2004268382A1 (en) 2005-03-10
NO20061479L (no) 2006-06-02
CA2537137C (en) 2013-05-28
CY1110506T1 (el) 2015-04-29
IL173909A (en) 2011-03-31
DE602004022061D1 (de) 2009-08-27
KR101116968B1 (ko) 2012-03-14

Similar Documents

Publication Publication Date Title
IL173909A0 (en) Use of modified cyclosporins for the treatment of hcv disorders
EP1644021A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
AU2003286567A8 (en) Methods for the treatment of skin disorders
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
AU2003274342A8 (en) Compositions for the treatment of autoimmune disorders
IL174014A0 (en) Methods for the treatment of endometriosis
AU2003298911A8 (en) Cyclosporins for the treatment of autoimmune diseases
GB0213869D0 (en) The treatment of pain
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
GB2388027B (en) Use of palatinose for the treatment of mental stress
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
AU2003273856A8 (en) Vr1 antagonists for the treatment of urological disorders
GB0201025D0 (en) The treatment of degenerative diseases
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
HRP20041159A2 (en) Combination for the treatment of airway disorders
GB0325957D0 (en) The treatment of pain
GB0322014D0 (en) The treatment of pain
TH0401003368A (th) การใช้ไซโคลสปอรินที่ถูกดัดแปลงสำหรับการรักษาความผิดปกติจาก hcv
ZA200508341B (en) Agents for the treatment of lower abdominal disorders
GB0203173D0 (en) The treatment of neurodegenerative disease
ZA200506714B (en) Methods and compositions for the treatment of gastrointestinal disorders
SI1644021T1 (sl) Postopki in sestavki za zdravljenje gastrointestinalnih motenj
GB0216978D0 (en) The treatment of pain
GB0310463D0 (en) Therapeutic agents for the treatment of bone conditions